Ani Pharmaceuticals (ANIP) Free Cash Flow (2010 - 2026)

Ani Pharmaceuticals has disclosed Free Cash Flow across 17 years of filings, most recently posting $52.3 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at $52.3 million, up 60.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $191.2 million (up 202.25% YoY), and the FY2025 annual result was $171.4 million, up 258.7% from the prior year.
• Free Cash Flow came in at $52.3 million for Q1 2026 at Ani Pharmaceuticals, up from $29.1 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $78.0 million in Q2 2025 to a low of -$19.2 million in Q1 2022.
• The 5-year median for Free Cash Flow is $20.8 million (2023), against an average of $20.6 million.
• Across the five-year window, Free Cash Flow tumbled 1138.34% in 2022 and jumped 11144.4% in 2025, its largest moves.
• Ani Pharmaceuticals' Free Cash Flow stood at -$7.5 million in 2022, then soared by 692.45% to $44.7 million in 2023, then tumbled by 99.42% to $259000.0 in 2024, then surged by 11144.4% to $29.1 million in 2025, then surged by 79.59% to $52.3 million in 2026.
• The last three Free Cash Flow figures came in at $52.3 million (Q1 2026), $29.1 million (Q4 2025), and $31.8 million (Q3 2025), per Business Quant data.